Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The prevalence of cognitive impairment in elderly diabetic patients is increasing, highlighting the importance of exploring strategies to prevent and ameliorate cognitive impairment in this population. Previous studies have focused mostly on improving cognition in elderly diabetic patients through three methods: medication, cognitive training, and lifestyle intervention. However, few studies have investigated the role of indoor biophilic environments in improving cognition. Biophilic environments improve human health by integrating natural elements into indoor architectural settings and have demonstrated efficacy in reducing stress and improving cognition. Therefore, it is worth exploring the effects of indoor biophilic environments on cognition in elderly diabetic patients. This study aims to investigate the effects of indoor biophilic environments on cognition in elderly diabetic patients, and the potential mechanisms.
Methods: This is a single-center, randomized controlled trial, which includes a short-term VR intervention and a long-term real environment intervention. In the short-term intervention trial, 64 diabetic patients over 60 years old are randomly assigned to 1 of 7 intervention groups or a control group. All intervention groups are constructed by single or various combinations of the 3 indoor biophilic elements: natural decorative paintings, indoor potted plants, and ornamental fish. The primary outcome of the short-term intervention trial is the cognitive scores assessed by DSST and BDS. In the long-term intervention trial, 240 diabetic patients over 60 years old will be randomly assigned to either the intervention group or the control group. The biophilic elements in long-term intervention will be determined based on the results of the short-term VR intervention trial. The primary outcomes of the long-term intervention trial are cognitive scores measured by DSST and MoCA, as well as concentrations of plasma p-tau181, esRAGE, and IL-6.
Conclusion: The findings will be utilized to develop a restorative living environment for elderly patients with diabetes to improve cognition.
Clinical Trial Registration: https://www.chictr.org.cn, identifier [ChiCTR2300072329].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880250 | PMC |
| http://dx.doi.org/10.3389/fpsyg.2025.1512175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial.
Eur J Heart Fail
September 2025
Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Aims: The estimated glucose disposal rate (eGDR) is a simple, non-invasive measure of insulin resistance. In this exploratory analysis of FINEARTS-HF, we evaluated whether lower eGDR, reflecting greater insulin resistance, is associated with adverse outcomes in heart failure (HF).
Methods And Results: The eGDR was calculated at baseline using waist circumference, glycated haemoglobin, and hypertension status.
Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC-HF II molecular substudy.
Eur J Heart Fail
September 2025
School of Cardiovascular & Metabolic Medicine and Science, James Black Centre, King's College London British Heart Foundation Centre of Excellence, London, UK.
Aims: Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion. This molecular substudy of the FERRIC-HF II trial tested the hypothesis that ferric derisomaltose (FDI) would improve electron transport chain activity, given its high dependence on iron-sulfur clusters which facilitate electron transfer during oxidative phosphorylation.
Methods And Results: Vastus lateralis skeletal muscle biopsies were taken before and 2 weeks after randomization.
Multi-Center Health Informatics to Examine the Implementation of Guideline-Directed Medical Therapy in Chronic Kidney Disease.
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDFSacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Diabetes management during the end of life.
Br J Nurs
September 2025
Macmillan Palliative and End of Life Care Practice Educator and Specialist Nurse Practitioner, Northampton General Hospital.
For individuals with diabetes, maintaining optimal glycaemic control is essential to reduce the risk of long-term complications. However, as patients approach the end of life, the emphasis on tight glycaemic targets becomes less relevant. Instead, the primary goal shifts to maintaining blood glucose levels within a range that minimises the risk of hypoglycaemia and prevents symptomatic hyperglycaemia, thereby ensuring comfort and quality of life.
View Article and Find Full Text PDF